Antimalarials in the treatment of systemic lupus erythematosus: A registry-based cohort study in Denmark

Lupus

Volumn 24, Issue 3, 2015, Pages 299-306

  Norgaard J C ^a   Stengaard Pedersen, K ^a   Norgaard M ^a   De Thurah, A ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

antimalarials; chloroquine; hydroxychloroquine; Systemic lupus erythematosus; time to treatment

Indexed keywords

ANGIOTENSIN II ANTAGONIST; ANTICOAGULANT AGENT; ANTIMALARIAL AGENT; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHOTREXATE; MYCOPHENOLIC ACID; PREDNISOLONE; RITUXIMAB; TACROLIMUS;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; CORTICOSTEROID THERAPY; DENMARK; DISEASE ACTIVITY; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRESCRIPTION; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TIME TO TREATMENT; CLINICAL PRACTICE; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; REGISTER;

ADRENAL CORTEX HORMONES; ADULT; ANTIMALARIALS; COHORT STUDIES; DENMARK; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; MIDDLE AGED; PRACTICE PATTERNS, PHYSICIANS'; REGISTRIES;

EID: 84922675142     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203314555351     Document Type: Article

References (45)

1. Laustrup H, Voss A, Green A, Junker P. Occurrence of systemic lupus erythematosus in a Danish community: An 8-year prospective study. Scand J Rheumatol. 2009 ; 38: 128-132
2. Lerang K, Gilboe I, Garen T, Thelle DS, Gran JT. High incidence and prevalence of systemic lupus erythematosus in Norway. Lupus. 2012 ; 21: 1362-1369
3. Feldman CH, Hiraki LT, Liu J, et al. Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000-2004. Arthritis Rheum. 2013 ; 65: 753-763
4. Voss A, Laustrup H, Hjelmborg J, Junker P. Survival in systemic lupus erythematosus, 1995-2010. A prospective study in a Danish community. Lupus. 2013 ; 22: 1185-1191
5. Schroeder TV, Schulze S, Hilsted J, Aldershvile J (eds) Basisbog i medicin & kirurgi. 3. udgave. ed, 2004, Munksgaard, Denmark, p.3.
6. Nikpour M, Urowitz MB, Gladman DD. Epidemiology of atherosclerosis in systemic lupus erythematosus. Curr Rheumatol Rep. 2009 ; 11: 248-254
7. Hak AE, Karlson EW, Feskanich D, Stampfer MJ, Costenbader KH. Systemic lupus erythematosus and the risk of cardiovascular disease: Results from the Nurses' Health Study. Arthritis Rheum. 2009 ; 61: 1396-1402
8. Tang C, Godfrey T, Stawell R, Nikpour M. Hydroxychloroquine in lupus: Emerging evidence supporting multiple beneficial effects. Intern Med J. 2012 ; 42: 968-978
9. Merrell M, Shulman LE. Determination of prognosis in chronic disease, illustrated by systemic lupus erythematosus. J Chronic Dis. 1955 ; 1: 12-32
10. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: A comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003 ; 82: 299-308
11. Lee SJ, Silverman E, Bargman JM. The role of antimalarial agents in the treatment of SLE and lupus nephritis. Nat Rev Nephrol. 2011 ; 7: 718-729
12. Tsakonas E, Joseph L, Esdaile JM, et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus. 1998 ; 7: 80-85
13. Bertsias G, Ioannidis JPA, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis. 2008 ; 67: 195-205
14. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: A systematic review. Ann Rheum Dis. 2010 ; 69: 20-28
15. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012 ; 71: 1771-1782
16. Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012 ; 64: 797-808
17. Danmarks Statistik, http://www.dst.dk/da/ (accessed 12th September 2012).
18. Pedersen CB, Gøtzsche H, Møller JO, Mortensen PB. The Danish Civil Registration System. A cohort of eight million persons. Dan Med Bull. 2006 ; 53: 441-449
19. Andersen TF, Madsen M, Jørgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull. 1999 ; 46: 263-268
20. Statens Serum Institut, http://www.ssi.dk/Sundhedsdataogit/Registre/Laegemiddelstatistikregisteret.aspx (accessed 15th December 2012).
21. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987 ; 40: 373-383
22. Jönsen A, Clarke AE, Joseph L, et al. Association of the Charlson Comorbidity Index with mortality in systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2011 ; 63: 1233-1237
23. de Groot V, Beckerman H, Lankhorst GJ, Bouter LM. How to measure comorbidity. A critical review of available methods. J Clin Epidemiol. 2003 ; 56: 221-229
24. Juel K, Helweg-Larsen K. The Danish registers of causes of death. Dan Med Bull. 1999 ; 46: 354-357
25. Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf. 2007 ; 16: 241-249
26. Fessler BJ, Alarcón GS, McGwin G, et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum. 2005 ; 52: 1473-1480
27. Schmajuk G, Yazdany J, Trupin L, Yelin E. Hydroxychloroquine treatment in a community-based cohort of patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2010 ; 62: 386-392
28. Mok CC, Tang SS, To CH, Petri M. Incidence and risk factors of thromboembolism in systemic lupus erythematosus: A comparison of three ethnic groups. Arthritis Rheum. 2005 ; 52: 2774-2782
29. Toloza SM, Uribe AG, McGwin G, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum. 2004 ; 50: 3947-3957
30. Meinão IM, Sato EI, Andrade LE, Ferraz MB, Atra E. Controlled trial with chloroquine diphosphate in systemic lupus erythematosus. Lupus. 1996 ; 5: 237-241
31. Williams HJ, Egger MJ, Singer JZ, et al. Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus. J Rheumatol. 1994 ; 21: 1457-1462
32. Wozniacka A, Lesiak A, Narbutt J, McCauliffe DP, Sysa-Jedrzejowska A. Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients. Lupus. 2006 ; 15: 268-275
33. Costedoat-Chalumeau N, Amoura Z, Hulot JS, et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum. 2006 ; 54: 3284-3290
34. Alarcón GS, McGwin G, Bertoli AM, et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: Data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis. 2007 ; 66: 1168-1172
35. Sisó A, Ramos-Casals M, Bové A, et al. Previous antimalarial therapy in patients diagnosed with lupus nephritis: Influence on outcomes and survival. Lupus. 2008 ; 17: 281-288
36. Ruiz-Irastorza G, Egurbide M, Pijoan J, et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus. 2006 ; 15: 577-583
37. Fessler BJ, Alarcón GS, McGwin G, et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum. 2005 ; 52: 1473-1480
38. Kitson AL, Rycroft-Malone J, Harvey G, McCormack B, Seers K, Titchen A. Evaluating the successful implementation of evidence into practice using the PARiHS framework: Theoretical and practical challenges. Implement Sci. 2008 ; 3: 1-1
39. Sokka T. Increases in use of methotrexate since the 1980s. Clin Exp Rheumatol. 2010 ; 28: S13 - S20
40. Bernatsky S, Peschken C, Fortin PR, et al. Medication use in systemic lupus erythematosus. J Rheumatol. 2011 ; 38: 271-274
41. Voss A, Green A, Junker P. Systemic lupus erythematosus in Denmark: Clinical and epidemiological characterization of a county-based cohort. Scand J Rheumatol. 1998 ; 27: 98-105
42. Eilertsen GO, Becker-Merok A, Nossent JC. The influence of the 1997 updated classification criteria for systemic lupus erythematosus: Epidemiology, disease presentation, and patient management. J Rheumatol. 2009 ; 36: 552-559
43. American College of Rheumatology, http://www.rheumatology.org/Practice/Clinical/Indexes/Systemic-Lupus-Erythematosus-Disease-Activity-Index-SELENA-Modification/ (accessed 5th May 2013).
44. American College of Rheumatology, http://www.rheumatology.org/Practice/Clinical/Indexes/Damage-Index-for-Systemic-Lupus-Erythematosus/ (accessed 5th May 2013).
45. Franco-Paredes C, Santos-Preciado JI. Problem pathogens: Prevention of malaria in travellers. Lancet Infect Dis. 2006 ; 6: 139-149